Tigulixostat

Tigulixostat
Clinical data
Other names	LC-350189
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid;
CAS Number	1287766-55-5 ;
PubChem CID	51039100 ;
DrugBank	DB18799 ;
ChemSpider	58954780 ;
UNII	WZ0PYQ6VLU ;
ChEMBL	ChEMBL3652780 ;
Chemical and physical data
Formula	C16H14N4O2
Molar mass	294.314 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC(C)N1C=C(C2=C1C=CC(=C2)N3C=C(C=N3)C(=O)O)C#N;
	InChI InChI=1S/C16H14N4O2/c1-10(2)19-8-11(6-17)14-5-13(3-4-15(14)19)20-9-12(7-18-20)16(21)22/h3-5,7-10H,1-2H3,(H,21,22); Key:JLQQRYOWGCIMMZ-UHFFFAOYSA-N;

Last updated January 02, 2026

Tigulixostat is an investigational new drug that is being evaluated for the treatment of gout.^[1] It is a xanthine oxidase inhibitor.^[2]

References

↑ "Tigulixostat - LG Chem". AdisInsight. Springer Nature Switzerland AG.
↑ Yip K, Braverman G, Yue L, Fields T (March 2024). "Pipeline Therapies for Gout". Current Rheumatology Reports. 26 (3): 69–80. doi:10.1007/s11926-023-01128-3. PMID 38133712.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Tigulixostat - LG Chem". AdisInsight. Springer Nature Switzerland AG.

[Yip_2025-2] Yip K, Braverman G, Yue L, Fields T (March 2024). "Pipeline Therapies for Gout". Current Rheumatology Reports. 26 (3): 69–80. doi:10.1007/s11926-023-01128-3. PMID 38133712.

[1]

[2]